Valsartan tab n / 160mg film about 30 pieces of ozone


Valsartan tab n / 160mg film about 30 pieces of ozone



Active substance:
1 tablet contains: valsartan – 40.0 mg; 80.0 mg or 160.0 mg.
Product form:
Tablets, film-coated 40 mg, 80 mg and 160 mg. At 7, 10, 14, 20, 28, 30, 56 tablets in blisters of PVC film and aluminum foil printed patent. At 7, 10, 14, 20, 28, 30, 40, 50 or 100 tablets per plastic jars for medicaments. One jar or 1, 2, 3, 4, 5, 6, 8 or 10 contour of cellular packaging together with instructions for use placed in a cardboard box (pack).
Hypersensitivity to any component of the drug; pregnant, planning to become pregnant; lactation; age of 18 years; severe liver dysfunction (more than 9 points on the Child-Pugh), biliary cirrhosis and cholestasis; simultaneous application of angiotensin II receptor antagonists, including valsartan, ACE inhibitors or with aliskiren in patients with diabetes.
160 mg
Arterial hypertension; Chronic heart failure patients receiving standard therapy with one or more drugs: diuretics, cardiac glycosides, ACE inhibitors or beta-blockers. Use of each of these drugs is not mandatory; to improve survival in patients after acute myocardial infarction complicated with left ventricular failure and / or left ventricular systolic dysfunction, the presence of stable hemodynamic parameters.
pharmachologic effect
Pharmacological group:
Angiotensin II receptor antagonist. ATC code S09SA03.
Pharmacological properties:
Valsartan – active specific angiotensin II receptor antagonist, intended for ingestion. Selectively blocking receptor subtype AT1, which is responsible for the effects of angiotensin II. A consequence of the blockade of AT1 receptors is to increase plasma concentrations of angiotensin II, which may stimulate the unlocked AT2-receptors. Valsartan does not have any pronounced agonist activity with respect to the AT1-receptor. The affinity of valsartan to the AT1 receptor subtype in about 20 000 times higher than for the AT2 receptor subtype. The probability of occurrence of cough in the application of valsartan is very low, due to the lack of effect on angiotensin converting enzyme (ACE), which is responsible for the degradation of bradykinin. Comparison of valsartan with an ACE inhibitor, found that the incidence of dry cough was significantly (p
Conditions of supply of pharmacies
Dosing and Administration
Pills taken by mouth without chewing. Hypertension: The recommended initial dose of drug is 80 Valsartan 1 mg once daily, regardless of race, age and sex of the patient. The antihypertensive effect develops in the first 2 weeks of treatment; maximum effect after 4 weeks. Those patients who have not achieved adequate therapeutic response, Valsartan daily dose of the drug can be increased to a maximum daily dose 320 mg or necessary to additionally use diuretics. Chronic heart failure: Valsartan recommended starting dose of the drug is 40 mg 2 times a day every day. Valsartan drug dose should be gradually increased for at least 2 weeks to 80 mg 2 times a day, and if tolerated – 160 mg 2 times a day. This may require dose reduction of concomitant diuretics. The maximum daily dose of valsartan formulation is 320 mg in 2 hours. To improve survival after myocardial infarction: the treatment should be initiated within 12 hours following myocardial infarction. The initial dose is 20 mg (1/2 tablets 40 mg) in 2 aza day. Increasing the dose titration is carried out (40 mg, 80 mg, 160 mg 2 times a day) for several weeks thereafter, to achieve a target dose of 160 mg 2 times a day. The maximum daily dose of 320 mg in 2 hours. Generally, achieving recommended dose to 80 mg 2 times a day by the end of the second week of treatment. Achieving maximum target dose of 160 mg 2 times daily is recommended that the end of the third month of therapy with Valsartan. Increasing the dose depends on the tolerance of the drug in the titration period. In the case of arterial hypotension, accompanied by clinical symptoms or impaired renal function should consider dose reduction. Evaluation of the patient in the period after myocardial infarction should include assessment of renal function. Use in patients aged over 65 years: in elderly patients dose adjustment is required. Patients with impaired renal functions in patients with impaired renal function correction dose is not required. There is currently no clinical evidence of drug application in patients with CC less than 10 ml / min. Patients with impaired hepatic function: patients with mild to moderate hepatic impairment nebiliarnogo genesis function without phenomena cholestasis drug should be used with caution, the daily dose should not exceed 80 mg.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg

OZONE generics

There are no reviews yet.

Add your review